Envoy Medical (NASDAQ: COCH) furnishes updated investor presentation for meetings

Rhea-AI Filing Summary

Envoy Medical, Inc. is providing an updated investor presentation that its management may use, with possible modifications, in meetings with current and potential investors. The presentation is attached as Exhibit 99.1 and includes forward-looking statements, with related risks and uncertainties described in the presentation. This information is being furnished under Regulation FD and is not deemed filed or incorporated into other securities law filings unless specifically referenced.

false 0001840877 0001840877 2025-12-16 2025-12-16 0001840877 COCH:ClassCommonStockParValue0.0001PerShareMember 2025-12-16 2025-12-16 0001840877 COCH:RedeemableWarrantsEachWholeWarrantMember 2025-12-16 2025-12-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 16, 2025

ENVOY MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40133		86-1369123
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4875 White Bear Parkway White Bear Lake, MN		55110
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 900-3277

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share		COCH		The Nasdaq Stock Market LLC
Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share		COCHW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

Envoy Medical, Inc. (the “Company”) is furnishing its updated Investor Presentation (the “Investor Presentation”) that management of the Company intends to use, possibly with modifications, in one or more meetings from time to time with current and potential investors.

The foregoing description of the Investor Presentation does not purport to be complete and is qualified in its entirety by reference to the complete text of the Investor Presentation attached as Exhibit 99.1 to this Current Report on Form 8-K. The Investor Presentation contains forward-looking statements. See Page 2 of the Investor Presentation for a discussion of certain forward-looking statements that are included therein and the risks and uncertainties related thereto.

The information set forth in this Item 7.01 of this Report, including without limitation the Investor Presentation, is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Investor Presentation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENVOY MEDICAL, INC.
December 16, 2025	By:	/s/ Brent T. Lucas
		Brent T. Lucas
		Chief Executive Officer

2

FAQ

What did Envoy Medical (COCH) disclose in this 8-K?

Envoy Medical disclosed that it is furnishing an updated Investor Presentation that management may use, with possible modifications, in meetings with current and potential investors.

How will Envoy Medical (COCH) use the updated investor presentation?

The updated investor presentation will be used by Envoy Medical’s management in one or more meetings from time to time with current and potential investors.

Where can investors find the updated Envoy Medical (COCH) investor presentation?

The updated investor presentation is attached as Exhibit 99.1 to the report and can be accessed as part of the company’s publicly available SEC materials.

Does the Envoy Medical (COCH) investor presentation contain forward-looking statements?

Yes. The investor presentation includes forward-looking statements, and Page 2 of the presentation discusses these statements and the related risks and uncertainties.

Is the Envoy Medical (COCH) investor presentation considered filed with the SEC?

No. The information in the investor presentation and in Item 7.01 is being furnished, not filed, and is not deemed filed or incorporated by reference into other securities law filings unless specifically referenced.

Which exhibit numbers are included with this Envoy Medical (COCH) report?

The report includes Exhibit 99.1 (Investor Presentation) and Exhibit 104 (Cover Page Interactive Data File embedded within the Inline XBRL document).